Xencor IncXNCR
What Xencor Inc does.
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb ® drug candidates with improved properties and multi-target mechanisms of action. We advance these candidates into clinical-stage development, where we are conducting Phase 1 and Phase 2 studies for a broad portfolio of programs, to determine which programs to advance into later stages of development and potentially commercialization, which programs we partner to optimize development, and which programs we discontinue.
Our approach to protein design includes engineering Fc domains, the parts of antibodies that interact with multiple segments of the immune system and control antibody structure. The Fc domain is constant and interchangeable across antibodies, and our engineered Fc domains can be readily substituted for natural Fc domains. These Fc domains provide specific features such as bispecific structure and extended half-life and serve as the scaffolds for our XmAb drug candidates.
We and our partners develop XmAb antibodies and other types of biotherapeutic drug candidates with improved properties and functionality, which can provide innovative approaches to potentially treating disease and clinical benefits over other treatment options. Applications of our protein engineering technologies include multi-specific antibodies that engage two or more targets simultaneously, creating entirely new biological mechanisms of anti-disease activity, or enhancement of antibody performance by increasing immune inhibitory activity, improving cytotoxicity, extending circulating half-life and stabilizing novel protein structures. Three marketed medicines have been developed with our XmAb protein engineering technologies.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $122.7M | $275.1M | $164.6M | $174.6M | $110.5M | $125.6M |
| Net income | -$69.3M | $82.6M | -$55.2M | -$133.1M | -$232.6M | -$91.9M |
| Free cash flow | -$15.5M | -$30.2M | -$14.0M | -$96.4M | -$208.3M | -$138.3M |
More on XNCR.
- Xencor Inc summary
- Xencor Inc financial statements
- Xencor Inc key metrics
- Xencor Inc health scores and style box
- Xencor Inc earnings
- Xencor Inc dividends
- Xencor Inc valuation
- Xencor Inc ownership and insiders
- Xencor Inc peers
Figures from Xencor Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.